Abstract
The extracts from the roots of Salvia miltiorrhiza Bunge (Danshen) are widely and traditionally used in the treatment of angina pectoris, acute myocardial infarct, hyperlipidemia and stroke in China and other Asian countries. In this study, we have investigated the role of P-glycoprotein (P-gp) in the intestinal absorption of tanshinone IIA (TSA), a major active constituent of Danshen, using several in vitro and in vivo models. The oral bioavailability of TSA was about 2.9-3.4% in rats, with non-linear pharmacokinetics when its dosage increased. In a single pass rat intestinal perfusion model, the permeability coefficients (Papp) based on TSA disappearance from the luminal perfusates (Plumen) were 6.2- to 7.2-fold higher (P < 0.01) than those based on drug appearance in mesenteric venous blood (Pblood). The Pblood, but not Plumen, was significantly increased when co-perfused with verapamil, or quinidine (both P-gp inhibitors). The uptake and efflux of TSA in confluent Caco-2 cells were significantly altered in the presence of verapamil, quinidine, MK-571, or probenecid. The transport of TSA across Caco-2 monolayers was pH-, temperature- and ATP-dependent. Furthermore, the transport from the apical (AP) to basolateral (BL) side of the Caco-2 monolayers was 3.3- to 8.5-fold lower than that from the BL to AP side, but such a polarized transport was attenuated by co-incubated verapamil or quinidine. A polarized transport was also observed in the control MDCKII cells and more apparent in MDR1-MDCKII monolayers, with the Papp values of TSA in the BL-AP direction being 7- to 9-fold higher in MDR1-MDCKII monolayers than those in the control MDCKII cells. Moreover, TSA significantly inhibited P-gp-mediated transport of digoxin in P-gp-overexpressing membrane vesicles with an IC50 of 2.6 μM, but stimulated vanadate-sensitive P-gp ATPase activity with estimated Km and Vmax values of 10.70 ± 0.69 μM and 67.65 ± 1.31 nmol/min/mg protein, respectively. TSA was extensively metabolized to tanshinone IIB (TSB), and two other oxidative metabolites in rat liver microsomes, but the formation rate of TSB in rat intestinal microsomes was only about 1/10 of that in liver microsomes. These findings indicate that TSA is a substrate and reversing agent for P-gp; and P-gp-mediated efflux of TSA into the gut lumen and the first-pass metabolism contribute to the low oral bioavailability. Further studies are needed to explore the role of other drug transporters and first-pass metabolism in the low bioavailability of TSA.
Keywords: Tanshinone IIA, P-glycoprotein, Intestinal Absorption, Bioavailability
Current Drug Metabolism
Title: Role of P-Glycoprotein in the Intestinal Absorption of Tanshinone IIA, a Major Active Ingredient in the Root of Salvia miltiorrhiza Bunge
Volume: 8 Issue: 4
Author(s): Xi-Yong Yu, Shu-Guang Lin, Zhi-Wei Zhou, Xiao Chen, Jun Liang, Pei-Qing Liu, Wei Duan, Balram Chowbay, Jing-Yuan Wen, Chun-Guang Li and Shu-Feng Zhou
Affiliation:
Keywords: Tanshinone IIA, P-glycoprotein, Intestinal Absorption, Bioavailability
Abstract: The extracts from the roots of Salvia miltiorrhiza Bunge (Danshen) are widely and traditionally used in the treatment of angina pectoris, acute myocardial infarct, hyperlipidemia and stroke in China and other Asian countries. In this study, we have investigated the role of P-glycoprotein (P-gp) in the intestinal absorption of tanshinone IIA (TSA), a major active constituent of Danshen, using several in vitro and in vivo models. The oral bioavailability of TSA was about 2.9-3.4% in rats, with non-linear pharmacokinetics when its dosage increased. In a single pass rat intestinal perfusion model, the permeability coefficients (Papp) based on TSA disappearance from the luminal perfusates (Plumen) were 6.2- to 7.2-fold higher (P < 0.01) than those based on drug appearance in mesenteric venous blood (Pblood). The Pblood, but not Plumen, was significantly increased when co-perfused with verapamil, or quinidine (both P-gp inhibitors). The uptake and efflux of TSA in confluent Caco-2 cells were significantly altered in the presence of verapamil, quinidine, MK-571, or probenecid. The transport of TSA across Caco-2 monolayers was pH-, temperature- and ATP-dependent. Furthermore, the transport from the apical (AP) to basolateral (BL) side of the Caco-2 monolayers was 3.3- to 8.5-fold lower than that from the BL to AP side, but such a polarized transport was attenuated by co-incubated verapamil or quinidine. A polarized transport was also observed in the control MDCKII cells and more apparent in MDR1-MDCKII monolayers, with the Papp values of TSA in the BL-AP direction being 7- to 9-fold higher in MDR1-MDCKII monolayers than those in the control MDCKII cells. Moreover, TSA significantly inhibited P-gp-mediated transport of digoxin in P-gp-overexpressing membrane vesicles with an IC50 of 2.6 μM, but stimulated vanadate-sensitive P-gp ATPase activity with estimated Km and Vmax values of 10.70 ± 0.69 μM and 67.65 ± 1.31 nmol/min/mg protein, respectively. TSA was extensively metabolized to tanshinone IIB (TSB), and two other oxidative metabolites in rat liver microsomes, but the formation rate of TSB in rat intestinal microsomes was only about 1/10 of that in liver microsomes. These findings indicate that TSA is a substrate and reversing agent for P-gp; and P-gp-mediated efflux of TSA into the gut lumen and the first-pass metabolism contribute to the low oral bioavailability. Further studies are needed to explore the role of other drug transporters and first-pass metabolism in the low bioavailability of TSA.
Export Options
About this article
Cite this article as:
Yu Xi-Yong, Lin Shu-Guang, Zhou Zhi-Wei, Chen Xiao, Liang Jun, Liu Pei-Qing, Duan Wei, Chowbay Balram, Wen Jing-Yuan, Li Chun-Guang and Zhou Shu-Feng, Role of P-Glycoprotein in the Intestinal Absorption of Tanshinone IIA, a Major Active Ingredient in the Root of Salvia miltiorrhiza Bunge, Current Drug Metabolism 2007; 8 (4) . https://dx.doi.org/10.2174/138920007780655450
DOI https://dx.doi.org/10.2174/138920007780655450 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem
Current Pharmacogenomics and Personalized Medicine In vivo Cancer Imaging with Semiconductor Quantum Dots
Current Pharmaceutical Analysis Molecular Imaging with Nucleic Acid Aptamers
Current Medicinal Chemistry Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry Apigenin and Breast Cancers: From Chemistry to Medicine
Anti-Cancer Agents in Medicinal Chemistry Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Challenges and Solutions in the Development of Genomic Biomarker Panels: A Systematic Phased Approach
Current Genomics Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Meta-analysis of NFKB1-94 ATTG Ins/Del Polymorphism and Risk of Breast Cancer
Current Drug Metabolism Antitumor and Antiviral Activity of Pentacyclic Triterpenes
Mini-Reviews in Organic Chemistry RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics BSA Au Clusters as a Probe for Enhanced Fluorescence Detection Using Multipulse Excitation Scheme
Current Pharmaceutical Biotechnology Gene Therapy for Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency
Current Gene Therapy Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Uncovering New Pharmacological Targets to Treat Neuropathic Pain by Understanding How the Organism Reacts to Nerve Injury
Current Pharmaceutical Design Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry